Previous studies have pointed out the anti-insulin resistance effects of DOP in different animal models, including leptin-deficient obese ob/ob mice, streptozotocin (STZ)-induced type 2 diabetes (T2D) mice, and diabetic nephropathy [57,58,59,60]. This evidence concerns the gene LEP and type 2 diabetes mellitus.